We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Sponsor content
214 result(s) found, displaying 11 to 20
-
-
Australian public assessment report (AusPar)Columvi (glofitamab), with obinutuzumab pretreatment, was provisionally approved for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. Columvi is not indicated for the treatment of patients with primary central nervous system lymphoma.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for VABYSMO faricimab 120 mg/mL solution for injection in a pre-filled syringe.
-
Australian public assessment report (AusPar)Gazyva (obinutuzumab) was approved as a pre-treatment to reduce the risk of cytokine release syndrome (CRS) induced by glofitamab.
-
Prescription medicine registrationActive ingredients: alectinib hydrochloride.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for TECENTRIQ SC atezolizumab 1875 mg/15 mL solution for injection vial.
-
-
Australian public assessment report (AusPar)Polivy (polatuzumab vedotin) was approved for the treatment of adult patients with previously untreated diffuse large B-cell lymphoma.
-
Cancellation by sponsorRequested by Roche Products Pty Ltd
-
Cancellation by sponsorRequested by Roche Products Pty Ltd